Vaxxirna was founded to address the fundamental limitations of conventional linear mRNA vaccine technologies, including short-lived immune responses, systemic reactogenicity, dependence on ultra-cold-chain logistics, and needle-based administration. These constraints limit how broadly current RNA vaccines can be deployed and who can benefit from them.

Through its proprietary viRNA™ circular RNA platform, Vaxxirna engineers next-generation vaccines designed to drive durable immunity for transformative impact across infectious disease.

By redesigning the RNA molecule itself, pairing it with a thermostable lipid nanoparticle (LNP) formulation, and enabling patch-based delivery via a microneedle array, Vaxxirna is building a platform capable of delivering robust, sustained immune protection with improved tolerability, simplified global distribution through reduced  cold chain dependance, and injection-free patient-friendly administration.